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The HIV drug resistance (HIVDR) prevention and assessment strategy, developed by the World Health
Organization (WHO) in partnership with HIVResNet, includes monitoring of HIVDR early warning
indicators, surveys to assess acquired and transmitted HIVDR, and development of an accredited HIVDR
genotyping laboratory network to support survey implementation in resource-limited settings. As of June
2011, 52 countries had implemented at least 1 element of the strategy, and 27 laboratories had been accredited.
As access to antiretrovirals expands under the WHO/Joint United Nations Programme on HIV/AIDS
Treatment 2.0 initiative, it is essential to strengthen HIVDR surveillance efforts in the face of increasing
concern about HIVDR emergence and transmission.
In 2010, 6.6 million adults and children in low- and
middle-income countries received antiretroviral therapy
(ART), representing a 22-fold increase from 2001 [1].
Successful ART scale-up in resource-limited settings
(RLSs) was realized using a public health approach,
including the use of standard protocols and simpli-
fied patient monitoring. The Joint United Nations
Programme on HIV/AIDS and the World Health
Organization (WHO) launched the Treatment 2.0
initiative in 2010, which is aimed at sustaining universal
access to treatment and maximizing the preventive
benefits of ART [2]. The treatment of millions of
human immunodeficiency virus (HIV)–infected patients
will inevitably be accompanied by the emergence and
transmission of HIV drug resistance (HIVDR); more-
over, the use of antiretroviral (ARV) drugs for prevention
has the potential to increase the prevalence of HIVDR.
In high-income countries, HIVDR testing of indi-
vidual patients is used to tailor regimen selection and
predict treatment response. However, in most, if not
all RLSs, HIVDR testing is neither routinely available
nor recommended for individual patient manage-
ment. Even with recent technological advancements,
it is unlikely that HIVDR testing for patient care will
be routinely available for millions of patients in the
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near future. Furthermore, the limited availability of alterna-
tive regimens restricts treatment change based on test results
[3]. HIVDR remains a threat to the long-term effectiveness of
ARV treatment [4–8]. The absence of accessible HIVDR
testing for individual patient care in RLSs necessitates that
efforts be intensified to optimize population-based ARV
treatment and to minimize HIVDR [9]. Unless carefully
monitored and contained, HIVDR has the potential to reduce
the efficacy of standard ART regimens in a high proportion of
patients in RLSs.
WORLD HEALTH ORGANIZATION HIVDR
STRATEGY
The WHO, in collaboration with HIVResNet, an advisory body
of international experts from .50 institutions, has led global
efforts for the prevention and assessment of HIVDR and has
developed a standardized, minimum-resource, population-
based strategy, which provides comparable data over time
and across regions [10]. The strategy consists of 3 main as-
sessment elements: HIVDR early warning indicators (EWIs)
and surveys of acquired and transmitted HIVDR [10–12]
for pediatric and adult populations. Additionally, the strat-
egy includes the development of a network of HIVDR tes-
ting (genotyping) laboratories that support public health
surveillance [13].
As of June 2011, 52 countries had implemented 1 or more
elements of WHO’s HIVDR prevention and assessment strategy,
and 27 laboratories had become members of the WHO HIVDR
laboratory network [14] (Figure 1). The purpose of this sup-
plement is to update the reader on global, regional, and country-
level results generated by the strategy, as well as resulting public
health actions. Additionally, this supplement reports a new
surveillance method to assess HIVDR in children aged ,18
months [15] and provides an update on the WHO external
quality assurance process for genotyping, as well as WHO-
supported operational research on the use of dried blood spots
as specimens for HIVDR testing [16, 17].
HIVDR EARLY WARNING INDICATORS
The foundation of the global HIVDR prevention and as-
sessment strategy is the annual monitoring of HIVDR EWIs
at all ART clinics or representative clinics [10]. HIVDR EWIs
assess prescribing practices, rates of retention, losses to
follow-up, population-level adherence to ART, drug supply
continuity, and virological suppression, which have been
shown to be major predictors of HIV disease progression,
death, and HIVDR [18–26]. Each EWI is associated with
a suggested clinic-level target. The WHO HIVDR EWIs and
their associated targets are listed in Table 1 of Bennett et al
(in this supplement [27]). EWI results provide clinic and
program managers with data about how their clinics perform
compared with international targets aimed at preventing
emergence of HIVDR [10]. To date, EWIs have been moni-
tored in 50 countries, assessing . 2000 clinics [27]. This
supplement contains the first global EWI report with data
obtained from 50 countries in 5 regions: Africa, Latin
America and the Caribbean, Southeast Asia, the Western
Pacific, and Eastern Europe. One regional report comes from
Latin America and the Caribbean. A report comes from
PharmAccess, which has implemented EWIs in 6 countries;
additionally, 4 country reports come from China, Papua
New Guinea, Vietnam, and Zimbabwe [27–33]. Although
these data represent early experiences, common themes have
emerged. The rate of patients lost to follow-up, rate of pa-
tient retention on first-line ART at 12 months, and patient
adherence as measured by on-time pill pickup often fall
below suggested targets and merit concern and investigation.
Additionally, EWI monitoring in several countries has
highlighted weaknesses in patient information systems that
have resulted in the inability to monitor specific EWIs. Re-
ported weaknesses in current data systems include in-
complete records, missing data, use of nonstandardized
records, and intraclinic and interclinic variability in data
recording. As a result of EWI monitoring, several countries
have taken steps to strengthen their information systems
[27–31, 34, 35].
SURVEYS OF ACQUIRED HIVDR
WHO prospective surveys of acquired HIVDR are performed
at sentinel ART clinics and supplement EWI data by
estimating the prevalence and patterns of HIVDR in adult
and pediatric populations experiencing ART failure [11]. At
each sentinel survey clinic, a cohort is formed of patients
initiating first-line ART. HIVDR genotyping is performed on
patients initiating ART, and HIV RNA quantification is
performed at the time that treatment is switched to second-line
or 12 months after ART initiation for patients remaining on
first-line treatment. In patients with detectable virus (.1000
copies/mL), genotyping is performed to characterize drug
resistance mutations. Other survey endpoints include loss to
follow-up, death, ART stop, or transfer to another ART clinic.
As of June 2011, 51 surveys of acquired HIVDR had been
performed in 13 countries. The results from 12 surveys
performed in 4 countries are published in this supplement
[36–40]. The overall prevalence of HIVDR prior to the ini-
tiation of ART remains relatively low, and the predicted level
of susceptibility observed among patients with HIVDR at
12 months suggests that the nucleoside reverse transcriptase
inhibitor component of currently recommended second-line
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regimens, in combination with a boosted protease inhibitor,
is likely to be effective for the majority surveyed [14]. No-
tably, in surveys published in this supplement, patient re-
sistance to nonnucleoside reverse transcriptase inhibitors at
the time of first-line ART initiation and treatment interrup-
tion are factors shown to predict virological failure at
12 months [36–39]. Additionally, surveys have concluded that
improved adherence, especially among young adults, and
improved defaulter tracing mechanisms may lead to im-
proved rates of virological suppression and HIVDR pre-
vention [36–39].
SURVEYS OF TRANSMITTED HIVDR
WHO TDR surveys use truncated sequential sampling and
small sample sizes of#47 to classify TDR as low (,5%), high
(.15%), or moderate (5%–15%) in populations likely to
have been recently infected [12, 41]. Where possible, these
surveys use remnant specimens and data from regularly
performed serosurveys that estimate HIV prevalence, which
are already in place in many RLSs. Results contribute to ART
policy decisions, including guidelines on ART regimens and
HIV prophylaxis.
As of June 2011, 53 TDR surveys have been performed in
22 countries [27]. Rates of TDR remain low in most areas and
populations assessed using WHO-recommended methods [14].
However, as ART rollout continues, increased rates of TDR may
occur. Recent publications, including reports published in this
supplement, document moderate (5%–15%) levels of TDR in
specific geographical regions [42–47]. These reports merit atten-
tion, warrant concern, and underscore the importance of routine
TDR surveillance as well as addressing and preventing HIVDR at
both national program and clinic levels.
NEW DIRECTIONS
Although monitoring of HIVDR EWIs are very important,
their uptake has generally been limited to pilot experiences.
Therefore, in 2011, WHO partnered with the Centers for
Disease Control and Prevention (CDC) and the US Presi-
dent’s Emergency Plan for AIDS Relief (PEPFAR) to initiate
a process that would update and simplify EWI guidance in
order to facilitate monitoring at larger numbers of ART
clinics. Simplifications of definitions and abstraction pro-
cedures are currently being considered that should facilitate
integration into existing program monitoring and evaluation
processes.
Additionally, in 2011, a less resource-intensive, cross-
sectional survey using lot quality assurance sampling was
developed to estimate acquired HIVDR. This cross-sectional
Figure 1. Countries implementing 1 or more elements of the World Health Organization human immunodeficiency virus drug resistance prevention and
assessment strategy, June 2011. This map is an approximation of actual country borders. Abbreviation: WHO, World Health Organization.
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survey should enable rapid generation of HIVDR data from
large numbers of ART clinics using significantly smaller
sample sizes than the current prospective method. Further-
more, this method will provide more comprehensive datasets
describing HIVDR in adult and pediatric patients experi-
encing ART failure at both 12 and .24 months after treat-
ment initiation. WHO and CDC/PEPFAR will pilot this
new method in several countries in 2012, and the results of
the pilot experience will be used to inform future global
surveillance guidance.
As prevention of mother-to-child transmission is scaled up,
fewer children are expected to become infected with HIV, but for
those who do, a substantial proportion will be expected to
harbor drug-resistant virus. Assessments of HIVDR in children
,18 months of age are performed to guide population-level,
first-line treatment in children. WHO and the CDC have de-
veloped a new surveillance protocol that uses remnant specimens
from early infant diagnosis to make nationally representative
statements about HIVDR in this population. This generic
protocol is described in this supplement, and it will be piloted in
Sub-Saharan Africa in 2012 by WHO and CDC/PEPFAR [15].
In conclusion, under the Treatment 2.0 initiative [2], millions
of infected people will initiate or be maintained on ART. Ad-
ditionally, many may be exposed to prevention strategies using
ARVs. Now more than ever, greater funding, infrastructure and
political will are urgently required to sustain and expand global
HIVDR surveillance efforts. Without the benefit of cumulative
standardized HIVDR surveillance data and a commitment on
the part of international organizations, national governments,
ART programs, funders, and implementing partners to identify
and address programmatic challenges associated with HIVDR,
we risk suboptimal population-level responses to current and
future ART regimens over the next decade.
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